Semax
Semax is a peptide, indexed here under Neuroactive peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Neuroactive peptides |
| CAS registry number | 80714-61-0[1] |
| PubChem CID | 9811102[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C37H51N9O10S[1] |
| Molecular weight | 813.9 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Semax is a synthetic peptide described in the retrieved literature as an analogue of the ACTH(4-10) fragment. A 2006 Brain Research paper reports that it regulates BDNF and trkB expression, and a 2001 Neuroscience Letters paper reports rapid induction of neurotrophin mRNAs in rat glial cell cultures.
A 2010 Cellular and Molecular Neurobiology paper reports that Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptors. A 2014 BMC Genomics paper reports effects on the expression of genes related to the immune and vascular systems, and a 2020 Genes paper examines protective properties of the ACTH(4-7)PGP form. A 1997 Russian-language review in Zhurnal Vysshei Nervnoi Deiatelnosti reports fifteen years of work on the compound.
[3, 4, 5, 6, 7, 8]Reported mechanism
Reported in the retrieved records to act on neurotrophin signalling, including BDNF and trkB expression; no single receptor target is established in the retrieved set.
[3, 4]Stated in the titles of the cited 2006 Brain Research and 2001 Neuroscience Letters papers.
Targets named in the cited records: BDNF, trkB receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Semax appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- ACTH(4-10) analogue
- Met-Glu-His-Phe-Pro-Gly-Pro
Where this page sits
Research records
Cited research records for Semax, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Semax
Compounds indexed next to it
- Selank — Neuroactive peptides
- Cerebrolysin — Neuroactive peptides
- Noopept — Neuroactive peptides
Class page: Neuroactive peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Semax?
Semax is a synthetic peptide described in the retrieved literature as an analogue of the ACTH(4-10) fragment. A 2006 Brain Research paper reports that it regulates BDNF and trkB expression, and a 2001 Neuroscience Letters paper reports rapid induction of neurotrophin mRNAs in rat glial cell cultures.
Which class is Semax indexed under?
Semax is indexed under Neuroactive peptides. The compounds grouped here are peptides whose retrieved literature examines effects in the nervous system.
What does the FDA application register show for Semax?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 9811102, ACTH (4-7), Pro-Gly-Pro-. PubChem, National Library of Medicine (2026). pubchem:9811102
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semax
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research (2006). pmid:16996037
- Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience letters (2001). pmid:11457573
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and molecular neurobiology (2010). pmid:19633950
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC genomics (2014). pmid:24661604
- Novel Insights into the Protective Properties of ACTH<sub>(4-7)</sub>PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (2020). pmid:32580520
- [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova (1997). pmid:9173745
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.